Nine sites. One point of accountability.
Multi-site studies rarely fail on science. They fail on coordination, on contract cycles, and on feasibility that was never realistic. Our model is built to remove those failure modes.
What you get
when you contract
with the network
A single master clinical trial agreement covers every site. One budget negotiation. One set of SOPs. One study director whose name is on the delivery.
- Central feasibility — answered from our own CTMS recruitment history in the indication, not from site optimism
- Single contract & budget — median 19 days from receipt to fully executed CTA across all participating sites
- Unified eSource & eISF — identical source structure at every location, so monitoring visits stop being archaeology
- Retained coordinators — average tenure of 4.1 years, which is why our studies do not lose continuity mid-enrolment
- Employed investigators — practising clinicians on our payroll, not sessional contractors fitting studies around a clinic list
- Continuous inspection readiness — TMF and delegation logs maintained to standard daily, auditable on two weeks' notice
- Participant registry — 18,000 consented volunteers, segmented by indication and pre-screened for common criteria
Therapeutic areas
We work in ten areas and decline studies outside them. Depth beats breadth when a protocol gets difficult.
Respiratory
Severe asthma, COPD, chronic cough. On-site spirometry, methacholine challenge and reversibility testing at five locations.
Dermatology
Atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo. Standardised photography and dedicated dermatology assessors.
Cardiometabolic
Type 2 diabetes, obesity, dyslipidaemia, heart failure. Central ECG reading and 24-hour ambulatory monitoring.
Vaccines
Prophylactic and therapeutic vaccine studies, including rapid-activation pandemic protocols and large healthy-volunteer cohorts.
Neurology
Migraine, epilepsy, multiple sclerosis, early Alzheimer's. Trained raters for cognitive and functional scales.
Rheumatology & other
Rheumatoid arthritis, axial spondyloarthritis, gastroenterology, renal, women's health and infectious disease.
Numbers from our CTMS, refreshed quarterly
We will show you the studies that went badly, too
Every site network publishes its wins. Ours is the only feasibility conversation we know of that starts with the four studies in the last three years where we missed our enrolment commitment, why, and what changed afterwards.
If a protocol's inclusion criteria will not recruit at our sites, we would rather tell you during feasibility than eighteen months into a rescue.
Send us a synopsis
We respond to feasibility requests within two working days with a genuine assessment — including a no, where a no is the honest answer.